These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 1673364)
1. Hypertrophic cardiomyopathy: prognosis with medical or surgical therapy. Blanchard DG; Ross J Clin Cardiol; 1991 Jan; 14(1):11-9. PubMed ID: 1673364 [TBL] [Abstract][Full Text] [Related]
2. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil. Sherrid MV; Shetty A; Winson G; Kim B; Musat D; Alviar CL; Homel P; Balaram SK; Swistel DG Circ Heart Fail; 2013 Jul; 6(4):694-702. PubMed ID: 23704138 [TBL] [Abstract][Full Text] [Related]
3. [Hypertrophic obstructive cardiomyopathy: current treatment, indications and results]. Delahaye JP; Azzano O Presse Med; 1994 May; 23(20):925-7. PubMed ID: 7937627 [TBL] [Abstract][Full Text] [Related]
4. [Hypertrophic cardiomyopathy (HCM). Surgical versus drug therapy]. Schulte HD; Gramsch-Zabel H; Schwartzkopff B; Gams E Z Kardiol; 1999 Mar; 88(3):163-72. PubMed ID: 10355066 [TBL] [Abstract][Full Text] [Related]
5. Management of hypertrophic cardiomyopathy in children. Seggewiss H; Rigopoulos A Paediatr Drugs; 2003; 5(10):663-72. PubMed ID: 14510624 [TBL] [Abstract][Full Text] [Related]
6. [Beneficial effects of disopyramide on left ventricular outflow obstruction in a case of hypertrophic obstructive cardiomyopathy]. Terrosu P; Franceschino V; Contini GM; Dore L; Ibba GV G Ital Cardiol; 1984 Jan; 14(1):63-6. PubMed ID: 6538527 [TBL] [Abstract][Full Text] [Related]
7. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline. Kajimoto K; Imai T; Minami Y; Kasanuki H Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829 [TBL] [Abstract][Full Text] [Related]
8. Advances in medical treatment of hypertrophic cardiomyopathy. Hamada M; Ikeda S; Shigematsu Y J Cardiol; 2014 Jul; 64(1):1-10. PubMed ID: 24735741 [TBL] [Abstract][Full Text] [Related]
9. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy. Matsubara H; Nakatani S; Nagata S; Ishikura F; Katagiri Y; Ohe T; Miyatake K J Am Coll Cardiol; 1995 Sep; 26(3):768-75. PubMed ID: 7642872 [TBL] [Abstract][Full Text] [Related]
14. Hypertrophic obstructive cardiomyopathy: mechanism of obstruction and response to therapy. Yoerger DM; Weyman AE Rev Cardiovasc Med; 2003; 4(4):199-215. PubMed ID: 14668688 [TBL] [Abstract][Full Text] [Related]
15. Disopyramide use in infants and children with hypertrophic cardiomyopathy. O'Connor MJ; Miller K; Shaddy RE; Lin KY; Hanna BD; Ravishankar C; Rossano JW Cardiol Young; 2018 Apr; 28(4):530-535. PubMed ID: 29513203 [TBL] [Abstract][Full Text] [Related]
16. Lifestyle Modification and Medical Management of Hypertrophic Cardiomyopathy. Heitner SB; Fischer KL Cardiol Clin; 2019 Feb; 37(1):45-54. PubMed ID: 30447715 [TBL] [Abstract][Full Text] [Related]
17. [Drug therapy of hypertrophic cardiomyopathy]. Hartmann A; Kaltenbach M; Hopf R Fortschr Med; 1992 Sep; 110(27):485-8. PubMed ID: 1358773 [TBL] [Abstract][Full Text] [Related]
18. Novel Pharmacotherapy for Hypertrophic Cardiomyopathy. Wong TC; Martinez M Cardiol Clin; 2019 Feb; 37(1):113-117. PubMed ID: 30447712 [TBL] [Abstract][Full Text] [Related]
19. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug. Verlinden NJ; Coons JC Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556 [TBL] [Abstract][Full Text] [Related]
20. Persisting effect of Ca(2+)-channel blockers on left ventricular function in hypertrophic cardiomyopathy after 14 years' treatment. Hartmann A; Schnell J; Hopf R; Kneissl G Angiology; 1996 Aug; 47(8):765-73. PubMed ID: 8712479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]